Prognostic factors and survival outcomes in patients with blast phase CML (CML-BP) in the tyrosine kinase inhibitor (TKI) era: cohort study of 477 patients

BACKGROUND: Outcomes in blast phase CML (CML-BP) are historically dismal. We sought to analyse the characteristics, prognostic factors and survival outcomes in patients with CML-BP in the TKI era. METHODS: All patients with CML-BP (n=477) were treated with a TKI at some point during the course of th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer
Asıl Yazarlar: Jain, Preetesh, Kantarjian, Hagop, Ghorab, Ahmed, Sasaki, Koji, Jabbour, Elias, Gonzalez, Graciela Nogueras, Kanagal-Shamanna, Rashmi, Issa, Ghayas C., Garcia-Manero, Guillermo, Devendra, KC, Dellasala, Sara, Pierce, Sherry, Konopleva, Marina, Wierda, William G., Verstovsek, Srdan, Daver, Naval, Kadia, Tapan M., Borthakur, Gautam, O’Brien, Susan, Estrov, Zeev, Ravandi, Farhad, Cortes, Jorge
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5673547/
https://ncbi.nlm.nih.gov/pubmed/28743165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30864
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller